ATPAF2 and Parkinson disease: It exerts its effects by binding to the electron transport chain complexes I and V named NDUFAB1 and ATPAF2, and an increase in p13 promotes the assembly of complex I. An experiment was performed to test whether p13 levels were altered in PD models; a reduction in p13 levels occurred due to mitochondrial dysfunction and cellular injury in the rotenone-induced PD model and MPTP-treated mice.